News & Events

NERI Presents at Drug Information Association Meeting in June

NERI scientists will chair two 90-minute speaking sessions and one poster presentation at the 44th Annual Drug Information Association (DIA) Meeting in Boston on June 22-26. These NERI thought leaders will moderate and present in three different DIA tracks: statistics, clinical research and development, and regulatory affairs. NERI will also exhibit at the conference and formally launch its specialized clinical research services to the private sector.

NERI President, Sonja McKinlay, will conduct a discussion titled, Selecting the Optimal Sample Size: Initial Realism or Adaptive Re-estimation. In partnership with Stuart Pocock of the London School of Hygiene and Tropical Medicine and Janet Wittes, Statistics Collaborative, Washington DC,
McKinlay will explain ways to estimate appropriate sample size, as a key factor in optimizing design efficiency (and ultimately minimizing study cost).
Rebecca Li, NERI’s Vice President of Clinical Research, will lead a session titled, Forging Partnerships with NIH-sponsored Clinical Trials and Networks.

In collaboration with Michael Domanski of the National Heart Lung and Blood Institute and Dean C. Winter, Vice President of Scientific and Clinical
Affairs for AtCor Medical Inc., Li will provide attendees with a perspective on how partnering with the NIH can be a cost-effective path to furthering
drug and device development in the private sector. Leveraging NIH-sponsored clinical trials and networks is an underutilized tool for biotechnology
and pharmaceutical companies.

Finally, Flora Sandra Siami, NERI’s Director of Regulatory Affairs, will present a poster titled, Ensuring Compliance and Quality in Global Clinical
Trials. The poster will provide attendees with diagnostic tools that can be incorporated into the management of global clinical trials. Attendees will be able to better evaluate the compliance and adherence of an international clinical research site.